Cargando…
Clinical characteristics associated with bone mineral density improvement after 1-year alendronate/vitamin d(3) or calcitriol treatment: Exploratory results from a phase 3, randomized, controlled trial on postmenopausal osteoporotic women in China
Baseline and on-treatment characteristics, including age, obesity, calcium intake, and bone turnover markers, may predict the bone mineral density (BMD) response in women with postmenopausal osteoporosis (PMO) to 1 to 2 years of antiresorptive therapy and/or vitamin D supplementation. This study aim...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6081166/ https://www.ncbi.nlm.nih.gov/pubmed/30075569 http://dx.doi.org/10.1097/MD.0000000000011694 |
_version_ | 1783345616480370688 |
---|---|
author | Liao, Er-Yuan Zhang, Zhen-Lin Xia, Wei-Bo Lin, Hua Cheng, Qun Wang, Li Hao, Yong-Qiang Chen, De-Cai Tang, Hai Peng, Yong-De You, Li He, Liang Hu, Zhao-Heng Song, Chun-Li Wei, Fang Wang, Jue Zhang, Lei |
author_facet | Liao, Er-Yuan Zhang, Zhen-Lin Xia, Wei-Bo Lin, Hua Cheng, Qun Wang, Li Hao, Yong-Qiang Chen, De-Cai Tang, Hai Peng, Yong-De You, Li He, Liang Hu, Zhao-Heng Song, Chun-Li Wei, Fang Wang, Jue Zhang, Lei |
author_sort | Liao, Er-Yuan |
collection | PubMed |
description | Baseline and on-treatment characteristics, including age, obesity, calcium intake, and bone turnover markers, may predict the bone mineral density (BMD) response in women with postmenopausal osteoporosis (PMO) to 1 to 2 years of antiresorptive therapy and/or vitamin D supplementation. This study aimed to explore clinical characteristics associated with 12-month BMD improvement in Chinese women with postmenopausal osteoporosis (PMO). In this post hoc analysis of a previous phase 3 multicenter, randomized controlled trial, Chinese PMO women who were treated with once weekly alendronate 70 mg/vitamin D3 5600 IU (ALN/D5600) or once daily calcitriol 0.25 mcg, and had measurements of 1-year lumbar spine BMD (LS-BMD) and on-treatment bone turnover markers (BTMs) were included in the analysis. In Chinese PMO patients on ALN/D5600, 1-year LS-BMD change was negatively correlated with age (β = −0.00084, P < .01), dietary calcium (β = −0.0017, P = .07), and procollagen type 1 N-terminal propeptide (P1NP) change at month 6 (β = −0.000469, P = .0016), but positively with body mass index (BMI) (β = 0.00128, P = .08); baseline P1NP above the median was associated with a significantly greater BMD percentage change at the lumbar spine (P = .02) and the total hip (P = .0001). In the calcitriol group, a significant 1-year LS-BMD increase was associated with BMI (β = 0.0023, P = .02), baseline P1NP (β = 0.00035, P = .0067), history of prior vertebral fracture(s) (β = 0.034, P < .0001) and baseline serum 25(OH)D level (β = −0.00083, P = .02). The presented findings from Chinese postmenopausal osteoporotic women suggested clinically meaningful baseline and on-treatment characteristics predicting BMD improvement after 1 year of ALN/D5600 treatment, which differed from calcitriol treatment with baseline identifiable associations. The study remained exploratory and further accumulation of evidence is needed. |
format | Online Article Text |
id | pubmed-6081166 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Wolters Kluwer Health |
record_format | MEDLINE/PubMed |
spelling | pubmed-60811662018-08-17 Clinical characteristics associated with bone mineral density improvement after 1-year alendronate/vitamin d(3) or calcitriol treatment: Exploratory results from a phase 3, randomized, controlled trial on postmenopausal osteoporotic women in China Liao, Er-Yuan Zhang, Zhen-Lin Xia, Wei-Bo Lin, Hua Cheng, Qun Wang, Li Hao, Yong-Qiang Chen, De-Cai Tang, Hai Peng, Yong-De You, Li He, Liang Hu, Zhao-Heng Song, Chun-Li Wei, Fang Wang, Jue Zhang, Lei Medicine (Baltimore) Research Article Baseline and on-treatment characteristics, including age, obesity, calcium intake, and bone turnover markers, may predict the bone mineral density (BMD) response in women with postmenopausal osteoporosis (PMO) to 1 to 2 years of antiresorptive therapy and/or vitamin D supplementation. This study aimed to explore clinical characteristics associated with 12-month BMD improvement in Chinese women with postmenopausal osteoporosis (PMO). In this post hoc analysis of a previous phase 3 multicenter, randomized controlled trial, Chinese PMO women who were treated with once weekly alendronate 70 mg/vitamin D3 5600 IU (ALN/D5600) or once daily calcitriol 0.25 mcg, and had measurements of 1-year lumbar spine BMD (LS-BMD) and on-treatment bone turnover markers (BTMs) were included in the analysis. In Chinese PMO patients on ALN/D5600, 1-year LS-BMD change was negatively correlated with age (β = −0.00084, P < .01), dietary calcium (β = −0.0017, P = .07), and procollagen type 1 N-terminal propeptide (P1NP) change at month 6 (β = −0.000469, P = .0016), but positively with body mass index (BMI) (β = 0.00128, P = .08); baseline P1NP above the median was associated with a significantly greater BMD percentage change at the lumbar spine (P = .02) and the total hip (P = .0001). In the calcitriol group, a significant 1-year LS-BMD increase was associated with BMI (β = 0.0023, P = .02), baseline P1NP (β = 0.00035, P = .0067), history of prior vertebral fracture(s) (β = 0.034, P < .0001) and baseline serum 25(OH)D level (β = −0.00083, P = .02). The presented findings from Chinese postmenopausal osteoporotic women suggested clinically meaningful baseline and on-treatment characteristics predicting BMD improvement after 1 year of ALN/D5600 treatment, which differed from calcitriol treatment with baseline identifiable associations. The study remained exploratory and further accumulation of evidence is needed. Wolters Kluwer Health 2018-08-03 /pmc/articles/PMC6081166/ /pubmed/30075569 http://dx.doi.org/10.1097/MD.0000000000011694 Text en Copyright © 2018 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by/4.0 This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0 |
spellingShingle | Research Article Liao, Er-Yuan Zhang, Zhen-Lin Xia, Wei-Bo Lin, Hua Cheng, Qun Wang, Li Hao, Yong-Qiang Chen, De-Cai Tang, Hai Peng, Yong-De You, Li He, Liang Hu, Zhao-Heng Song, Chun-Li Wei, Fang Wang, Jue Zhang, Lei Clinical characteristics associated with bone mineral density improvement after 1-year alendronate/vitamin d(3) or calcitriol treatment: Exploratory results from a phase 3, randomized, controlled trial on postmenopausal osteoporotic women in China |
title | Clinical characteristics associated with bone mineral density improvement after 1-year alendronate/vitamin d(3) or calcitriol treatment: Exploratory results from a phase 3, randomized, controlled trial on postmenopausal osteoporotic women in China |
title_full | Clinical characteristics associated with bone mineral density improvement after 1-year alendronate/vitamin d(3) or calcitriol treatment: Exploratory results from a phase 3, randomized, controlled trial on postmenopausal osteoporotic women in China |
title_fullStr | Clinical characteristics associated with bone mineral density improvement after 1-year alendronate/vitamin d(3) or calcitriol treatment: Exploratory results from a phase 3, randomized, controlled trial on postmenopausal osteoporotic women in China |
title_full_unstemmed | Clinical characteristics associated with bone mineral density improvement after 1-year alendronate/vitamin d(3) or calcitriol treatment: Exploratory results from a phase 3, randomized, controlled trial on postmenopausal osteoporotic women in China |
title_short | Clinical characteristics associated with bone mineral density improvement after 1-year alendronate/vitamin d(3) or calcitriol treatment: Exploratory results from a phase 3, randomized, controlled trial on postmenopausal osteoporotic women in China |
title_sort | clinical characteristics associated with bone mineral density improvement after 1-year alendronate/vitamin d(3) or calcitriol treatment: exploratory results from a phase 3, randomized, controlled trial on postmenopausal osteoporotic women in china |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6081166/ https://www.ncbi.nlm.nih.gov/pubmed/30075569 http://dx.doi.org/10.1097/MD.0000000000011694 |
work_keys_str_mv | AT liaoeryuan clinicalcharacteristicsassociatedwithbonemineraldensityimprovementafter1yearalendronatevitamind3orcalcitrioltreatmentexploratoryresultsfromaphase3randomizedcontrolledtrialonpostmenopausalosteoporoticwomeninchina AT zhangzhenlin clinicalcharacteristicsassociatedwithbonemineraldensityimprovementafter1yearalendronatevitamind3orcalcitrioltreatmentexploratoryresultsfromaphase3randomizedcontrolledtrialonpostmenopausalosteoporoticwomeninchina AT xiaweibo clinicalcharacteristicsassociatedwithbonemineraldensityimprovementafter1yearalendronatevitamind3orcalcitrioltreatmentexploratoryresultsfromaphase3randomizedcontrolledtrialonpostmenopausalosteoporoticwomeninchina AT linhua clinicalcharacteristicsassociatedwithbonemineraldensityimprovementafter1yearalendronatevitamind3orcalcitrioltreatmentexploratoryresultsfromaphase3randomizedcontrolledtrialonpostmenopausalosteoporoticwomeninchina AT chengqun clinicalcharacteristicsassociatedwithbonemineraldensityimprovementafter1yearalendronatevitamind3orcalcitrioltreatmentexploratoryresultsfromaphase3randomizedcontrolledtrialonpostmenopausalosteoporoticwomeninchina AT wangli clinicalcharacteristicsassociatedwithbonemineraldensityimprovementafter1yearalendronatevitamind3orcalcitrioltreatmentexploratoryresultsfromaphase3randomizedcontrolledtrialonpostmenopausalosteoporoticwomeninchina AT haoyongqiang clinicalcharacteristicsassociatedwithbonemineraldensityimprovementafter1yearalendronatevitamind3orcalcitrioltreatmentexploratoryresultsfromaphase3randomizedcontrolledtrialonpostmenopausalosteoporoticwomeninchina AT chendecai clinicalcharacteristicsassociatedwithbonemineraldensityimprovementafter1yearalendronatevitamind3orcalcitrioltreatmentexploratoryresultsfromaphase3randomizedcontrolledtrialonpostmenopausalosteoporoticwomeninchina AT tanghai clinicalcharacteristicsassociatedwithbonemineraldensityimprovementafter1yearalendronatevitamind3orcalcitrioltreatmentexploratoryresultsfromaphase3randomizedcontrolledtrialonpostmenopausalosteoporoticwomeninchina AT pengyongde clinicalcharacteristicsassociatedwithbonemineraldensityimprovementafter1yearalendronatevitamind3orcalcitrioltreatmentexploratoryresultsfromaphase3randomizedcontrolledtrialonpostmenopausalosteoporoticwomeninchina AT youli clinicalcharacteristicsassociatedwithbonemineraldensityimprovementafter1yearalendronatevitamind3orcalcitrioltreatmentexploratoryresultsfromaphase3randomizedcontrolledtrialonpostmenopausalosteoporoticwomeninchina AT heliang clinicalcharacteristicsassociatedwithbonemineraldensityimprovementafter1yearalendronatevitamind3orcalcitrioltreatmentexploratoryresultsfromaphase3randomizedcontrolledtrialonpostmenopausalosteoporoticwomeninchina AT huzhaoheng clinicalcharacteristicsassociatedwithbonemineraldensityimprovementafter1yearalendronatevitamind3orcalcitrioltreatmentexploratoryresultsfromaphase3randomizedcontrolledtrialonpostmenopausalosteoporoticwomeninchina AT songchunli clinicalcharacteristicsassociatedwithbonemineraldensityimprovementafter1yearalendronatevitamind3orcalcitrioltreatmentexploratoryresultsfromaphase3randomizedcontrolledtrialonpostmenopausalosteoporoticwomeninchina AT weifang clinicalcharacteristicsassociatedwithbonemineraldensityimprovementafter1yearalendronatevitamind3orcalcitrioltreatmentexploratoryresultsfromaphase3randomizedcontrolledtrialonpostmenopausalosteoporoticwomeninchina AT wangjue clinicalcharacteristicsassociatedwithbonemineraldensityimprovementafter1yearalendronatevitamind3orcalcitrioltreatmentexploratoryresultsfromaphase3randomizedcontrolledtrialonpostmenopausalosteoporoticwomeninchina AT zhanglei clinicalcharacteristicsassociatedwithbonemineraldensityimprovementafter1yearalendronatevitamind3orcalcitrioltreatmentexploratoryresultsfromaphase3randomizedcontrolledtrialonpostmenopausalosteoporoticwomeninchina |